<html>
<head>
<title>CHAPTER 126-Z TERMINAL PATIENTS' RIGHT TO TRY ACT</title>
<!-- Hide metadata
<titlename>TITLE X PUBLIC HEALTH</titlename>
<chapter>CHAPTER 126-Z TERMINAL PATIENTS' RIGHT TO TRY ACT</chapter>
-->
</head>
<body>
<center><h1>TITLE X<br>PUBLIC HEALTH</h1></center>
<center><h2>CHAPTER 126-Z<br>TERMINAL PATIENTS' RIGHT TO TRY ACT</h2></center>
<center><h3>Section 126-Z:1</h3></center>
&nbsp;&nbsp;&nbsp;<b> 126-Z:1 Definitions.  &#150;</b>
<codesect>
In this chapter:
<br>
&nbsp&nbsp&nbsp
I. "Eligible patient'' means a person to whom all of the following apply:
<br>
&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp
(a) The person has a terminal illness as determined by the person's physician and a consulting physician.
<br>
&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp
(b) The person's physician has determined that the person has no comparable or satisfactory United States Food and Drug Administration (FDA) approved treatment options available to diagnose, monitor, or treat the disease or condition involved and that the probable risk to the person from the investigational drug, biological product, or device is not greater than the probable risk from the disease or condition.
<br>
&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp
(c) The person has received a prescription or recommendation from the person's physician for an investigational drug, biological product, or device.
<br>
&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp
(d) The person has given written informed consent for the use of the investigational drug, biological product, or device or, if the patient is a minor or lacks the mental capacity to provide informed consent, a parent or legal guardian has given written informed consent on the patient's behalf.
<br>
&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp
(e) The person has documentation from the person's physician that the person has met the requirements of this paragraph.
<br>
&nbsp&nbsp&nbsp
II. "Investigational drug, biological product, or device'' means a drug, biological product, or device that has successfully completed phase one of a clinical trial, but has not been approved for general use by the FDA and remains under investigation in a clinical trial.
<br>
&nbsp&nbsp&nbsp
III. "Physician'' means the licensed physician who is providing medical care or treatment to the eligible patient for the terminal illness.
<br>
&nbsp&nbsp&nbsp
IV. "Terminal illness'' means a disease that, without life-sustaining procedures, will result in death in the near future or a state of permanent unconsciousness from which recovery is unlikely.
</codesect>
<sourcenote>
<p><b>Source.</b>  2016, 206:2, eff. June 6, 2016.</p>
</sourcenote>
<center><h3>Section 126-Z:2</h3></center>
&nbsp;&nbsp;&nbsp;<b> 126-Z:2 Availability of Investigational Drugs, Biological Products, or Devices;  Costs;  Coverage. &#150;</b>
<codesect>
<br>
&nbsp&nbsp&nbsp
I. A manufacturer of an investigational drug, biological product, or device may make available an investigational drug, biological product, or device to eligible patients pursuant to this chapter.  A manufacturer may:
<br>
&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp
(a) Provide an investigational drug, biological product, or device to an eligible patient without receiving compensation.
<br>
&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp
(b) Require an eligible patient to pay the costs of or associated with the manufacture of the investigational drug, biological product, or device.
<br>
&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp
(c) Require an eligible patient to participate in data collection relating to the use of the investigational drug, biological product, or device.
<br>
&nbsp&nbsp&nbsp
II. This chapter shall not require a health care insurer or any state agency to provide coverage for the cost of any investigational drug, biological product, or device.
<br>
&nbsp&nbsp&nbsp
III. Nothing in this chapter shall require the manufacturer of an investigational drug, biological product, or device to include an eligible patient in a particular clinical trial or study.
</codesect>
<sourcenote>
<p><b>Source.</b>  2016, 206:2, eff. June 6, 2016.</p>
</sourcenote>
<center><h3>Section 126-Z:3</h3></center>
&nbsp;&nbsp;&nbsp;<b> 126-Z:3 Liability of Physician;  Facility. &#150;</b>
<codesect>
<br>
&nbsp&nbsp&nbsp
I. Notwithstanding any provision of law to the contrary, the board of medicine shall not revoke, fail to renew, or take any other action against a physician's license issued pursuant to RSA 329 based solely on a physician's recommendation to an eligible patient regarding or prescription for or treatment with an investigational drug, biological product, or device.
<br>
&nbsp&nbsp&nbsp
II. Notwithstanding any provision of law to the contrary, the department of health and human services shall not take action against a facility licensed under RSA 151 based solely on the institution's participation in the treatment or use of an investigational drug, biological product, or device under this chapter.
</codesect>
<sourcenote>
<p><b>Source.</b>  2016, 206:2, eff. June 6, 2016.</p>
</sourcenote>
<center><h3>Section 126-Z:4</h3></center>
&nbsp;&nbsp;&nbsp;<b> 126-Z:4 Private Cause of Action.  &#150;</b>
<codesect>
Nothing in this chapter shall be construed to create a private cause of action against a manufacturer of an investigational drug, biological product, or device or against any other person or entity involved in the care of an eligible patient using the investigational drug, biological product, or device for any harm done to the eligible patient resulting from the investigational drug, biological product, or device, if the manufacturer or other person or entity is complying in good faith with the terms of this chapter and has exercised reasonable care.
</codesect>
<sourcenote>
<p><b>Source.</b>  2016, 206:2, eff. June 6, 2016.</p>
</sourcenote>
<center><h3>Section 126-Z:5</h3></center>
&nbsp;&nbsp;&nbsp;<b> 126-Z:5 Severability.  &#150;</b>
<codesect>
If any provision of this chapter, or the application thereof to any person or circumstance is held invalid, the invalidity does not affect the other provisions or applications of the chapter which can be given effect without the invalid provisions or applications and to this end the provisions of this chapter are severable.
</codesect>
<sourcenote>
<p><b>Source.</b>  2016, 206:2, eff. June 6, 2016.</p>
</sourcenote>
</body>
</html>
